Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Noveris Health SciencesMYCOF 25 Cash Ratio is 0.25 as of Jun. 2026, which is at its 10-year median of 0.25. GuruFocus rates MYCOF with a GF Score™ of 25/100 and a GF Value™ of $0.52 (Significantly Overvalued). Among 968 Drug Manufacturers companies, Noveris Health Sciences ranks worse than 70.56% on this metric.
Noveris Health Sciences has a Cash Ratio of 0.25. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Noveris Health Sciences's Cash Ratio or its related term are showing as below:
MYCOF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.25 Max: 3.91
Current: 0.25
During the past 13 years, Noveris Health Sciences's highest Cash Ratio was 3.91. The lowest was 0.01. And the median was 0.25.
MYCOF's Cash Ratio is ranked worse than 70.56% of 968
companies
in the Drug Manufacturers industry
Industry Median: 0.57
vs MYCOF: 0.25
Noveris Health Sciences (OTCPK:MYCOF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Noveris Health Sciences Cash Ratio Related Terms
Noveris Health Sciences Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Noveris Health Sciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noveris Health Sciences Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Noveris Health Sciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Noveris Health Sciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noveris Health Sciences (MYCOF) has a Cash Ratio of 0.25 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Noveris Health Sciences and its competitors. This is near median its historical median of 0.25. Over the past decade, Noveris Health Sciences' Cash Ratio has ranged from 0.01 to 3.91. According to the industry distribution chart, Noveris Health Sciences ranks #683 out of 968 companies in the Drug Manufacturers industry, placing it in the top 70.6%.
Is Noveris Health Sciences' Cash Ratio too high?
Noveris Health Sciences' current Cash Ratio of 0.25 is near median its 10-year median of 0.25. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 3.91. The Drug Manufacturers industry median Cash Ratio is 0.57. Noveris Health Sciences' value of 0.25 is 56.1% below this industry median. Based on the distribution chart, Noveris Health Sciences ranks #683 out of 968 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Noveris Health Sciences has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Noveris Health Sciences ranks #683 out of 968 companies for Cash Ratio. This places Noveris Health Sciences in the lower half of its industry. The industry median Cash Ratio is 0.57. Noveris Health Sciences' value of 0.25 is 56.1% below this benchmark. Historically, Noveris Health Sciences' own Cash Ratio has ranged from 0.01 to 3.91 over the past decade. While the company's 10-year median is 0.25 vs. the industry median of 0.57, Noveris Health Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.57, based on 968 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noveris Health Sciences's current Cash Ratio of 0.25 is 56.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Noveris Health Sciences and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noveris Health Sciences's current Cash Ratio is 0.25, which is near median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Noveris Health Sciences (MYCOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $0.73 — trading 40.4% above its estimated fair value. The current Cash Ratio is 0.25, which is near median its 10-year median of 0.25 and 56.1% below the Drug Manufacturers industry median of 0.57. Noveris Health Sciences' overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Cash Ratio is 0.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noveris Health Sciences (MYCOF) Overvalued in 2026?
Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued.
The current stock price of $0.73 is trading 40.4% above its estimated GF Value™ of $0.52.
GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.
Key valuation signals for MYCOF:
Cash Ratio: 0.25 (near median its 10-year median of 0.25)
GF Value™: $0.52 vs. price of $0.73 (40.4% above fair value)
Industry Position: 56.1% below the Drug Manufacturers median (#683 of 968)
No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
25GF Score
Get the complete analysis for MYCOF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MYCOF has been successfully added to your 
